Ozempic, Wegovy, Mounjaro and Zepbound went from diabetes-clinic vocabulary to dinner-table conversation in about three years. A KFF poll from November 2025 found that 18% of American adults had taken a GLP-1 drug at some point, and 12% were taking one at the time. Almost every major health show has weighed in, some breathlessly, some skeptically, a few with real scientific depth. This guide leaves the celebrity gossip and the culture war to our companion piece on how Ozempic culture took over podcasts. It sticks to the four questions people on the drugs (or thinking about them) keep asking, with the trial evidence for each and the episode that answers it best.
How much weight do people lose?
More than any previous drug for obesity. In the STEP trials, semaglutide (Wegovy) produced average weight loss around 15% of body weight. In SURMOUNT-1, tirzepatide (Zepbound) at its highest dose averaged about 21% over 72 weeks, territory previously reserved for bariatric surgery. Then the SELECT trial showed semaglutide cutting major cardiovascular events by about 20% in people with obesity and established heart disease, which moved the story from the bathroom scale to the cardiology ward.
The clearest explanation of why the drugs work so well comes from Huberman Lab. Andrew Huberman's June 2024 conversation with Dr. Zachary Knight, a UCSF physiologist and HHMI investigator who studies the hunger neurons these drugs act on, walks through the mechanism: slowed gastric emptying, signaling in the hypothalamus and brainstem, and the drop in "food noise" that patients describe. Knight also explains why the body fights back after large losses, with rising hunger and falling energy expenditure, a part most coverage skips.
What happens to muscle?
This is the physiological risk that clinician guests raise most often. Rapid weight loss takes lean tissue with it, and in body-composition substudies a quarter to more than a third of the weight lost on these drugs has been lean mass (a measure that includes water and organ tissue as well as muscle). The protection is unglamorous: resistance training and much more protein, which is why a protein-products industry has pivoted to GLP-1 users.
The Peter Attia Drive has the deepest coverage of this. Attia, a Stanford- and Hopkins-trained physician focused on longevity medicine and author of the bestseller Outlive, devoted an AMA in March 2023 to comparing semaglutide and tirzepatide, then followed it with AMA #64 in October 2024 on body composition, resistance training while on the drugs, compounded versions and oral options. His position is consistent: these are important drugs, the lean-mass problem is real, and the off-label optimization crowd is well ahead of the data.
For the kitchen side, ZOE Science & Nutrition is the most practical listen. The UK show, fronted by Jonathan Wolf with epidemiologist Tim Spector as a regular, ran a 2026 episode with ZOE nutrition scientists Dr. Federica Amati and Professor Sarah Berry on protecting muscle, bone and brain health on weight-loss injections. When people eat 30 to 40% fewer calories, protein, fiber and micronutrient density suddenly matter far more, and the episode turns that into concrete meal-level advice.
What happens when you stop?
For most people the weight comes back. When the STEP 1 investigators followed participants for a year after stopping semaglutide, they had regained about two-thirds of the weight they had lost, and improvements in blood pressure, cholesterol and blood sugar drifted back toward baseline. The authors concluded that obesity needs ongoing treatment, and the careful episodes treat these as long-term medications for a chronic disease. Attia's AMA covers discontinuation directly; Knight's explanation of the body's defense of its old weight tells you why it happens.
The appetite effect may also reach beyond food. Patient accounts of quieter "food noise" often mention drinking, and a small randomized trial of 48 adults with alcohol use disorder, published in JAMA Psychiatry in 2025, found that semaglutide reduced how much they drank in a lab session and lowered their cravings. The authors called for larger trials before anyone draws firm conclusions. For the recovery side of that story, see our guide to podcasts on addiction and recovery.
Who pays, and who gets left out?
Access is where the story moved in 2026. Cash-pay telehealth, a compounding-pharmacy gray market that grew during the shortages, and insurers refusing to cover obesity treatment created a two-tier system. Prices have since fallen through direct-to-consumer deals, and a Medicare pilot running from July 2026 to the end of 2027 offers eligible beneficiaries Wegovy, Zepbound or the new GLP-1 pills for a $50 monthly copay. Even so, cash prices still run from about $149 to $699 a month.
The sharpest critics of that system are on Maintenance Phase. Aubrey Gordon (author of What We Don't Talk About When We Talk About Fat) and journalist Michael Hobbes built their show on debunking diet culture, and their October 2023 Ozempic episode is the strongest counterargument in audio. It covers the drug's origins in Gila monster venom research, the "end of obesity" headlines, the shortages and compounders, Novo Nordisk's marketing, and the way access splits along income lines. Mark Hyman, the functional-medicine physician behind The Dr. Hyman Show (formerly The Doctor's Farmacy), comes at it from the food side: he accepts that the drugs work and questions a system that medicates the consequences of an ultra-processed food supply instead of fixing the food.
Journalist Johann Hari brought the patient's view. His book Magic Pill grew out of his own time on Ozempic, which he started injecting in January 2023, and on The Diary Of A CEO in April 2024 he laid out the benefits alongside the twelve risks his reporting turned up. The Daily from The New York Times has tracked the insurance fights and pricing deals as news.
Telehealth GLP-1 programs: what to check before paying
Podcast ad breaks are full of weight-loss telehealth programs, and they sell different things. Some prescribe branded Wegovy or Zepbound and send the prescription to a pharmacy, so your insurer or a manufacturer's cash program pays for the drug. Others bundle a membership fee with compounded semaglutide or tirzepatide made by a partner pharmacy. Compounded versions are not FDA-approved, and once the FDA declared the shortages over, the legal room for mass-made copies narrowed sharply. Before you pay, ask which exact drug you will get and from which pharmacy. Check whether a licensed clinician reviews your history and blood work, and who adjusts the dose or handles side effects such as nausea. Find out what the monthly fee covers and how to cancel. Attia's AMA on compounded versions and oral options is a useful primer before signing up.
A four-episode course
If you want the practical picture in four sittings, take one episode per question. Start with Huberman's Zachary Knight episode for how much weight the drugs remove and why the body resists. Follow it with Attia's AMA #64 for muscle, dosing and what happens after stopping (the full AMA is for subscribers; the free preview covers the main points). Then play ZOE's episode with Federica Amati for the protein, fiber and training plan that goes with the medication. Finish with Maintenance Phase's Ozempic episode for cost, access and the critique of how the drugs are sold. Together they cover what a ten-minute doctor's appointment usually has no time for. New shows covering the drugs tend to surface first in the Health & Fitness and Nutrition charts.
Shows mentioned here appear in Reason.fm's daily-updated Health & Fitness and Nutrition rankings.
This article looks at how podcasts discuss the topic and is not medical advice. Talk to a doctor or other qualified clinician about your own situation before starting, changing or stopping any treatment.